coronavirus
cov
envelop
virus
positivesens
singlestrand
rna
associ
variou
natur
host
cov
divid
alpha
beta
gamma
delta
group
beta
group
compos
b
c
subgroup
fig
among
six
cov
infect
human
hcov
includ
alpha
group
beta
subgroup
sever
acut
respiratori
syndrom
cov
sarscov
beta
subgroup
b
middl
east
respiratori
syndrom
cov
merscov
beta
subgroup
c
centuri
sarscov
merscov
emerg
human
popul
caus
sever
pulmonari
diseas
alarmingli
high
casefat
rate
sarscov
infect
first
appear
china
quickli
spread
global
epidem
countri
infect
death
nearli
mortal
merscov
emerg
saudi
arabia
spread
throughout
middl
east
second
pandem
merscov
occur
south
korea
caus
superspread
event
third
fourthgener
case
infect
world
health
organ
report
laboratoryconfirm
case
merscov
infect
includ
death
case
fatal
countri
august
wwwwhointemergenciesmerscoven
meanwhil
remain
common
hcov
usual
infect
human
upper
respiratori
tract
caus
common
cold
also
respons
sever
even
fatal
diseas
children
elderli
immunocompromis
patient
scenario
suggest
common
hcov
might
also
pose
lethal
threat
human
note
hcov
rapidli
evolv
isol
novel
genom
continu
identifi
exist
sarslik
cov
slcov
merslik
cov
mlcov
also
pose
great
threat
public
health
worldwid
recent
studi
identifi
type
slcov
whose
spike
protein
highli
resembl
sarscov
slcov
could
use
sarscov
receptor
ie
angiotensinconvert
directli
enter
permiss
human
cell
without
need
adapt
addit
mlcov
tylonycteri
bat
cov
shown
recogn
merscov
receptor
infect
human
cell
either
introduct
two
singl
mutat
protein
help
exogen
proteas
histor
perspect
zoonot
cov
harbor
strong
abil
cross
speci
barrier
infect
human
rapidli
unpredict
illustr
newli
emerg
hcov
thu
develop
specif
drug
target
singl
hcov
would
ineffect
newli
emerg
hcov
sinc
broadspectrum
antihcov
drug
current
avail
clinic
use
incumb
search
common
conserv
target
site
base
exist
hcov
glycoprotein
type
transmembran
glycoprotein
play
import
role
mediat
viral
infect
common
hcov
protein
consist
two
subunit
fig
subunit
bind
cellular
receptor
receptorbind
domain
rbd
follow
conform
chang
subunit
allow
fusion
peptid
insert
host
target
cell
membran
heptad
repeat
region
subunit
form
homotrimer
assembl
expos
three
highli
conserv
hydrophob
groov
surfac
bind
heptad
repeat
sixhelix
bundl
core
structur
form
fusion
process
help
bring
viral
cellular
membran
close
proxim
viral
fusion
entri
fig
thu
protein
import
target
protein
develop
specif
drug
particular
rbd
good
target
site
rbdspecif
antibodi
rbdbase
vaccin
previous
exhibit
effect
antivir
activ
protect
effect
block
bind
viru
host
receptor
howev
evolutionari
perspect
rbd
cov
part
highli
mutabl
region
thu
ideal
target
site
broadspectrum
antivir
inhibitor
develop
sarscov
rbdspecif
antibodi
fail
block
infect
mediat
protein
contrast
hr
region
subunit
conserv
among
variou
hcov
play
pivot
role
hcov
infect
form
mediat
viral
fusion
fig
furthermor
mode
interact
conserv
among
cov
residu
locat
e
g
posit
helic
interact
residu
posit
helic
fig
previou
studi
report
peptid
deriv
ctermin
hr
region
class
viral
fusion
protein
envelop
virus
includ
respiratori
syncyti
viru
rsv
ebola
viru
paramyxovirus
nipah
viru
murin
hepat
viru
mhv
could
competit
bind
viral
ntermin
hr
effect
inhibit
viral
infect
therefor
reason
specul
could
also
good
target
develop
fusion
inhibitor
highli
pathogen
hcov
other
report
peptid
deriv
region
sarscov
merscov
protein
competit
inhibit
viral
format
therebi
prevent
viral
fusion
entri
host
cell
exampl
peptid
deriv
sarscov
spike
protein
region
abl
inhibit
sarscov
entri
manner
similar
merscov
infect
howev
note
peptid
lack
broadspectrum
antivir
activ
heterolog
hcov
exampl
peptid
fail
crossinhibit
merscov
sarscov
infect
respect
furthermor
cov
fusion
core
hr
region
divid
two
group
short
hr
merscov
sarscov
hr
long
hr
hr
differ
short
long
hr
aris
insert
amino
acid
long
hr
increas
difficulti
design
broadspectrum
peptid
fusion
inhibitor
address
challeng
herein
report
success
screen
peptid
broadspectrum
fusion
inhibitori
activ
furthermor
modifi
peptid
show
promis
potenc
breadth
inhibit
infect
multipl
hcov
vivo
studi
demonstr
administr
via
nasal
rout
exhibit
highli
protect
effect
safeti
profil
highlight
clinic
potenti
moreov
structur
studi
complex
differ
hcov
explain
conserv
basi
interact
indic
region
could
serv
promis
target
site
develop
broadspectrum
pancov
fusion
inhibitor
basi
fusion
core
structur
previous
report
peptid
deriv
merscov
respect
fig
two
peptid
display
good
interact
locat
conserv
hr
region
multipl
hcov
sequenc
comparison
synthes
peptid
term
fig
notabl
observ
acid
insert
hr
two
ie
systemat
assess
inhibitori
activ
peptid
differ
hcov
develop
multipl
cellcel
fusion
assay
mediat
protein
variou
hcov
fig
consist
previou
result
inhibitori
activ
cellcel
fusion
mediat
merscov
protein
concentr
inhibit
wherea
show
littl
inhibitori
activ
hcov
smediat
cellcel
fusion
assay
even
concentr
fig
tabl
similarli
specif
inhibit
sarscov
smediat
cellcel
fusion
hand
peptid
deriv
two
ie
show
potent
broad
inhibitori
activ
smediat
cellcel
fusion
valu
rang
respect
effect
inhibitori
activ
includ
merscov
sarscov
smediat
fusion
fig
tabl
exhibit
broad
potent
fusion
inhibitori
activ
valu
merscov
sarscov
respect
fig
tabl
unexpectedli
peptid
thu
residu
shorter
exhibit
effect
activ
cellcel
fusion
cellcel
fusion
among
exhibit
moder
inhibitori
effect
cellcel
fusion
fig
thu
compar
hcov
peptid
exhibit
excel
selfspecif
fusion
inhibitori
activ
wherea
show
broadspectrum
potent
fusion
inhibitori
activ
smediat
cellcel
fusion
fig
tabl
also
measur
circular
dichroism
found
peptid
alon
exhibit
limit
rang
fig
contrast
mixtur
peptid
respect
exhibit
high
melt
transit
temperatur
tm
valu
rang
fig
impli
bind
differ
hcov
form
stabl
complex
therebi
block
fusion
previous
report
introduct
neg
posit
charg
amino
acid
glu
e
ly
k
posit
helix
fusion
inhibitori
peptid
form
intramolecular
salt
bridg
result
substanti
enhanc
peptid
stabil
solubl
antivir
activ
use
similar
design
optim
sequenc
introduc
glu
ly
appropri
site
peptid
increas
solubl
therebi
antivir
activ
peptid
moreov
basi
structur
merscov
also
introduc
mutat
site
expect
involv
bind
enhanc
fusion
inhibitori
activ
peptid
tabl
among
seri
optim
peptid
peptid
show
gradual
increas
solubl
excel
inhibitori
activ
cellcel
fusion
assay
final
peptid
exhibit
potent
pancov
antivir
fusion
activ
valu
rang
tabl
hcov
cellcel
fusion
assay
exhibit
even
effect
inhibitori
activ
autolog
peptid
akin
ancestor
deriv
short
fusion
core
also
abl
potent
inhibit
cellcel
fusion
mediat
protein
harbor
long
fusion
core
result
underscor
broadspectrum
antihcov
potenti
fig
e
tabl
furthermor
also
superior
pharmaceut
properti
solubl
phosphatebuff
salin
pb
water
increas
respect
compar
origin
togeth
result
establish
import
framework
platform
subsequ
develop
potenti
therapeut
tabl
slcov
includ
cov
manifest
potenti
human
infect
assess
breadth
fusion
inhibitori
activ
demonstr
establish
cellcel
fusion
assay
mediat
protein
slcov
fig
notabl
mani
studi
suggest
divers
receptorbind
motif
rbm
slcov
rbd
play
import
role
bind
cellular
receptor
serv
effect
target
site
develop
covspecif
antibodi
vaccin
specif
rbm
cov
similar
ident
sarscov
antibodi
target
sarscov
rbd
could
prevent
infect
mediat
protein
contrast
sequenc
slcov
ident
sarscov
fig
correspondingli
exhibit
greater
inhibitori
activ
autolog
peptid
cellcel
fusion
mediat
protein
three
slcov
test
fig
f
h
peptid
show
inhibitori
activ
cellcel
fusion
mediat
cov
protein
fig
h
pseudoviru
assay
good
model
mimic
process
viru
entri
target
cell
wide
use
previou
studi
assess
inhibitori
activ
antivir
agent
relat
cov
infect
also
use
pseudoviru
assay
assess
inhibitori
activ
differ
pseudotyp
hcov
merscov
pseudoviru
infect
assay
show
inhibitori
activ
valu
respect
fig
similarli
also
effect
block
sarscov
pseudoviru
infect
valu
respect
fig
meanwhil
demonstr
antivir
activ
pseudotyp
infect
valu
respect
fig
k
consist
result
cellcel
fusion
assay
inhibit
pseudotyp
viru
infect
valu
respect
prevent
pseudoviru
infect
valu
respect
fig
n
contrast
exhibit
inhibitori
activ
viral
infect
fig
peptid
show
inhibitori
activ
infect
pseudovirus
fig
p
previous
report
fail
assembl
pseudotyp
thu
perform
pseudoviru
infect
assay
viru
collect
pseudoviru
infect
hcov
slcov
could
effici
block
indic
broadspectrum
antivir
activ
infect
panhcov
includ
slcov
blamvpr
assay
sensit
model
character
inhibitori
mechan
activ
antivir
agent
membran
fusion
assay
wide
use
assess
membran
fusion
activ
variou
virus
includ
ebola
viru
henipaviru
develop
blamvpr
assay
merscov
sarscov
clarifi
fusion
inhibitori
mechan
found
effect
inhibit
entri
merscov
blamvpr
virion
sarscov
blamvpr
virion
cell
cell
respect
dosedepend
manner
fig
thu
confirm
act
hcov
fusion
inhibitor
subsequ
evalu
inhibitori
activ
live
hcov
infect
includ
merscov
found
could
effect
inhibit
infect
replic
hcov
cellular
level
dosedepend
manner
fig
q
even
surpass
autolog
optim
peptid
merscov
valu
respect
meanwhil
also
exhibit
equal
effect
inhibitori
activ
infect
valu
respect
compar
fig
unfortun
global
prohibit
handl
live
sarscov
virolog
laboratori
could
test
inhibitori
activ
sarscov
replic
respiratori
tract
primari
target
tissu
hcov
infect
investig
preclin
potenti
peptid
administ
via
intranas
rout
assess
distribut
within
respiratori
tract
observ
fluoresc
signal
mainli
upper
lower
respiratori
tract
mice
fig
b
compar
pbstreat
mice
lung
obtain
mice
exhibit
significantli
higher
fluoresc
signal
p
n
fig
c
togeth
result
suggest
intranas
wide
distribut
whole
respiratori
tract
enrich
lung
also
note
administ
intranas
could
detect
signific
amount
sever
extrapulmonari
organ
includ
liver
kidney
spleen
anim
suggest
could
enter
blood
circul
organ
fig
b
observ
suggest
intranas
administr
could
also
benefici
multiorgan
infect
system
infect
hcov
common
merscov
infect
next
assess
protect
effect
vivo
merscov
infect
mous
model
mous
model
treat
newborn
mice
dose
mgkg
pb
min
challeng
tissu
cultur
infecti
dose
bodi
weight
mice
viral
control
group
decreas
start
day
postinfect
dpi
mice
succumb
infect
dpi
mortal
fig
e
g
contrast
final
surviv
rate
mice
prophylact
therapeut
group
respect
fig
bodi
weight
either
appear
normal
prophylact
rapidli
recov
dpi
therapeut
fig
meanwhil
test
viral
titer
brain
mice
group
dpi
infecti
viru
readili
detect
viral
control
group
wherea
infecti
viru
titer
limit
detect
log
prophylact
mice
low
therapeut
mice
fig
howev
infecti
viru
titer
brain
mice
die
therapeut
treatment
high
brain
viral
control
mice
without
treatment
viral
titer
brain
surviv
mice
therapeut
treatment
normal
control
mice
undetect
fig
consist
brain
mice
die
therapeut
treatment
exhibit
similar
histopatholog
chang
viral
control
mice
ie
similar
amount
vacuol
degener
infiltr
fig
contrast
brain
surviv
mice
therapeut
treatment
normal
control
mice
show
appar
histopatholog
chang
fig
evalu
prophylact
therapeut
potenti
merscov
infect
took
advantag
wellcharacter
transgen
tg
mice
global
express
human
dipeptidyl
peptidas
iv
viral
receptor
treat
mice
pb
min
challeng
merscov
likewis
weight
loss
tg
mice
treat
merscov
challeng
insignific
rapidli
recov
dpi
untreat
mice
progress
lost
signific
weight
succumb
infect
within
dpi
mortal
fig
h
j
contrast
surviv
rate
prophylact
therapeut
group
respect
fig
h
j
yield
infecti
virus
lung
use
end
point
assess
efficaci
merscov
infect
unabl
recov
infecti
viru
prophylact
therapeut
group
sharp
contrast
untreat
control
fig
togeth
result
indic
peptid
broad
potent
prophylact
therapeut
efficaci
hcov
infect
safeti
obvious
import
develop
clinic
applic
therefor
first
test
vitro
cytotox
variou
target
cell
cytotox
concentr
mm
time
higher
inhibit
hcov
smediat
cellcel
fusion
pseudoviru
entri
fig
investig
cytotox
vivo
continu
administ
mice
pb
lowdos
mgkg
highdos
mgkg
intranas
rout
everi
day
week
record
bodi
weight
chang
follow
week
fig
mice
high
lowdos
group
live
normal
appar
differ
weight
gainloss
observ
compar
pbstreat
mice
meanwhil
use
enzymelink
immunosorb
assay
elisa
measur
antibodi
sera
mice
week
intranas
administr
antibodi
detect
either
group
pbstreat
group
fig
basi
distribut
intranas
administr
fig
b
postul
could
penetr
airblood
barrier
enter
blood
circul
becom
enrich
import
organ
liver
kidney
therefor
examin
level
alanin
aminotransferas
alt
fig
creatinin
fig
sera
mice
alt
creatinin
show
signific
differ
p
time
point
pbstreat
group
suggest
nasal
applic
high
low
dose
affect
mous
hepat
renal
function
compar
potenti
histopatholog
chang
pbstreat
group
week
administr
hematoxylin
eosin
stain
lung
liver
kidney
spleen
section
mice
treat
differ
dose
exhibit
patholog
abnorm
compar
control
mice
treat
pb
fig
none
organ
show
evid
cell
degener
necrosi
infiltr
inflammatori
factor
henc
appear
gener
safe
via
nasal
applic
investig
structur
basi
pancov
inhibitori
effect
peptid
crystal
complex
peptid
three
repres
hcov
includ
pathogen
sarscov
merscov
amino
acid
longer
crystal
structur
mer
sar
solv
molecular
replac
refin
final
resolut
respect
tabl
three
structur
snugli
fit
hydrophob
groov
form
two
adjac
helic
obliqu
antiparallel
manner
fig
c
produc
structur
resembl
postfus
state
correspond
hcov
fig
notabl
bind
site
coincid
nativ
fig
result
indic
presenc
would
preclud
bind
onto
correspond
core
therebi
block
format
indispens
step
hostvir
membran
fusion
henc
administr
peptid
would
block
cellular
entri
hcov
fig
three
structur
peptid
adopt
mix
secondari
structur
conform
fig
c
central
region
fold
fiveturn
helix
pack
two
neighbor
helic
via
extens
hydrophob
interact
core
differ
hcov
illustr
electrostat
surfac
residu
involv
hydrophob
pack
shown
stick
model
residu
locat
within
fiveturn
helix
form
strong
hydrophob
interact
core
fig
electrostat
polar
interact
residu
locat
within
fiveturn
helix
region
interact
residu
side
chain
hydrophil
interact
fig
rest
adopt
extend
conform
except
one
extra
turn
form
ctermin
end
around
structur
fig
right
panel
extend
region
polar
interact
side
chain
residu
main
chain
residu
domin
compar
fig
b
side
chain
polar
interact
cluster
either
end
helic
region
interweav
extens
hbond
network
like
help
secur
helic
region
correct
regist
fig
hydrophob
residu
extend
region
also
insert
bulki
side
chain
hydrophob
pocket
surfac
core
residu
fig
strengthen
adhes
extend
region
onto
core
hydrophob
pocket
ridg
exist
surfac
core
fig
correspondingli
observ
two
kind
hydrophob
interact
core
particular
certain
residu
insert
hydrophob
side
chain
pocket
core
fig
shown
orang
stick
model
hereaft
name
buri
residu
residu
pack
side
chain
hydrophob
ridg
core
fig
shown
yellow
stick
model
hereaft
name
ridgepack
residu
note
residu
mediat
hydrophob
interact
buri
ridgepack
residu
conserv
across
hcov
fig
bottom
panel
residu
shade
orang
yellow
residu
involv
polar
electrostat
interact
also
manifest
high
level
similar
across
hcov
fig
bottom
panel
residu
box
cyan
red
thu
would
abl
form
similar
hydrophob
hydrophil
interact
observ
homolog
model
fig
togeth
extens
highli
conserv
hydrophob
hydrophil
interact
core
endow
abil
bind
core
differ
hcov
henc
capabl
block
associ
differ
onto
correspond
core
fig
peptid
outcompet
selfderiv
merscov
cellcel
fusion
pseudoviru
infect
assay
therefor
also
compar
interact
fig
left
panel
fig
hydrophob
interact
similar
compar
fig
left
panel
fig
left
panel
nevertheless
form
side
chain
hydrophil
interact
compar
fig
left
panel
fig
middl
panel
like
account
better
cellcel
fusion
pseudoviru
infect
assay
fig
similar
sequenc
align
across
hcov
reveal
acid
insert
also
exist
region
fig
insert
render
helic
four
turn
longer
helic
region
five
turn
long
much
shorter
nineturn
helix
nevertheless
buri
residu
extend
region
equival
neatli
insert
side
chain
correspond
hydrophob
pocket
fig
although
residu
locat
extend
region
equival
within
region
fig
consequ
hydrophob
interact
compromis
comparison
compar
fig
right
panel
fig
left
panel
furthermor
total
polar
electrostat
interact
occur
includ
five
side
chain
seven
side
chain
interact
fig
b
right
panel
togeth
extens
hydrophob
hydrophil
interact
preserv
high
affin
toward
long
hcov
form
structur
short
sarscov
merscov
long
highlight
broad
structur
compat
accommod
differ
hcov
thu
consolid
broadspectrum
inhibitori
effect
pancov
effect
broadspectrum
antihcov
drug
vaccin
current
avail
clinic
notwithstand
rbd
protein
propos
promis
target
develop
specif
antibodi
vaccin
exampl
rbdspecif
antibodi
exhibit
inhibitori
activ
merscov
infect
nevertheless
administr
singleantibodi
could
result
emerg
escap
mutat
merscov
rbd
unfortun
cov
rbd
hypervari
throughout
evolut
led
mark
differ
host
receptor
usag
differ
hcov
even
host
receptor
use
differ
hcov
frequent
target
differ
bind
site
host
receptor
therefor
specif
rbdtarget
antibodi
vaccin
inevit
lack
broadspectrum
activ
hcov
infect
exampl
menacheri
et
al
found
sarscov
rbdspecif
antibodi
could
protect
mice
infect
chimer
viru
protein
although
high
homolog
sarscov
bind
host
receptor
lag
time
emerg
human
cov
outbreak
develop
new
prophylact
treatment
vaccin
concern
thu
urgent
need
develop
new
broadspectrum
drug
target
conserv
site
current
circul
futur
emerg
hcov
prepar
futur
outbreak
yet
unknown
hcov
earli
seri
peptid
deriv
chr
domain
later
report
highli
potent
inhibitori
activ
membran
fusion
infect
valu
low
nanomolar
level
subsequ
numer
viru
fusion
inhibitori
peptid
overlap
sequenc
class
membran
fusion
protein
envelop
virus
includ
rsv
ebola
viru
paramyxovirus
nipah
viru
also
report
bosch
et
al
discov
solubl
peptid
deriv
mhv
protein
region
inhibit
viru
cell
entri
suggest
glycoprotein
cov
class
fusogen
abil
form
membran
fusion
process
bosch
jiang
group
independ
report
peptid
deriv
region
sarscov
protein
could
interact
peptid
region
form
inhibit
sarscov
membran
fusion
sarscov
infect
moder
potenc
lu
et
al
report
peptid
deriv
merscov
could
competit
inhibit
format
therebi
prevent
fusion
viru
host
cell
previou
studi
found
fusion
inhibitor
could
block
sarscov
pseudoviru
infect
display
broadspectrum
inhibitori
activ
thu
unclear
whether
good
target
site
develop
broadspectrum
antihcov
inhibitor
identifi
panhcov
fusion
inhibit
target
site
prefer
also
develop
potenti
panhcov
inhibitor
infect
multipl
hcov
human
respiratori
tract
success
establish
multipl
hcov
smediat
cellcel
fusion
assay
determin
crossinhibitori
spectrum
deriv
respect
hcov
unexpectedli
found
harbor
broadspectrum
bind
activ
manifest
fusion
inhibitori
activ
hcov
smediat
cellcel
fusion
optim
improv
antivir
activ
solubl
optim
peptid
exhibit
broad
potent
fusion
inhibitori
activ
infect
hcov
slcov
variou
vitro
model
ie
cellcel
fusion
assay
pseudotyp
live
viral
infect
assay
assess
prophylact
protect
effect
intranas
administr
merscov
mous
model
exhibit
effect
prevent
protect
effect
mous
model
accept
vivo
safeti
profil
furthermor
vivo
pharmacokinet
profil
safeti
studi
help
us
acquir
use
data
potenti
human
clinic
trial
futur
potenc
peptid
inhibit
correspond
viruscel
fusion
vari
significantli
exampl
peptid
potent
peptid
yet
potent
peptid
known
sarscov
enter
target
cell
mainli
plasma
endosom
membran
fusion
respect
merscov
could
infect
target
cell
via
plasma
endosom
membran
fusion
vast
differ
seen
potenc
thu
suggest
limit
number
peptid
get
endosom
inhibit
viruscel
fusion
therefor
increas
cell
permeabl
fusion
inhibitori
peptid
expect
enhanc
potenc
peptid
recent
report
addit
hydrocarbon
stapl
palmit
acid
group
merscov
fusion
inhibitori
peptid
significantli
improv
antivir
potenc
pharmacokinet
properti
near
futur
use
similar
approach
improv
antivir
activ
recent
studi
report
sever
emerg
slcov
includ
potenti
infect
human
high
virul
evolut
direct
gene
recombin
sarscov
found
hr
sequenc
slcov
sarscov
predict
could
prevent
infect
slcov
expect
effici
inhibit
slcov
cellcel
fusion
consist
previou
studi
herein
also
fail
establish
pseudoviru
use
backbon
vector
therefor
assess
antivir
effect
pseudoviru
infect
found
exhibit
effect
inhibitori
activ
two
slcov
addit
anim
cov
within
cov
famili
close
hcov
bovin
coronaviru
bcov
mhv
hr
sequenc
cov
similar
indic
peptid
like
also
effect
virus
one
intrigu
question
manifest
pancov
inhibitori
activ
hcov
substanti
longer
fig
dock
onto
core
result
sever
steric
clash
figur
shown
thu
understand
would
broadspectrum
activ
toward
fig
time
sequenc
align
sarscov
merscov
provid
clue
limit
inhibit
breadth
although
residu
mediat
hydrophob
shade
orang
yellow
side
chain
hydrophil
interact
box
cyan
conserv
differ
sequenc
variabl
exist
posit
ridgepack
residu
fig
thu
focus
analysi
residu
surround
environ
differ
hcov
core
solv
structur
mer
sar
fit
side
chain
neatli
hydrophob
pocket
two
core
fig
second
fourth
panel
nevertheless
previous
report
structur
sarscov
fusion
core
equival
sarscov
would
occupi
caviti
loos
fig
third
panel
equival
merscov
could
fulli
buri
side
chain
owe
polar
natur
thr
residu
fig
first
panel
thu
val
effect
fit
hydrophob
caviti
posit
ala
seen
thr
seen
fig
total
observ
four
ridgepack
interact
core
ridg
bind
surround
polar
posit
charg
residu
merscov
sarscov
surround
polar
neg
charg
residu
fig
top
panel
side
chain
surround
residu
shown
stick
model
posit
polar
pair
sertyr
appear
suitabl
serleu
pair
accommod
opposit
electrostat
environ
differ
hcov
moreov
aromat
ring
tyr
could
also
form
addit
polar
interact
side
chain
differ
hcov
fig
likewis
ridg
bind
also
exhibit
better
shape
complementar
met
ile
collect
seem
optim
amino
acid
choic
abovement
critic
posit
like
account
uniqu
pancov
inhibitori
activ
natur
state
protein
present
cov
surfac
inact
receptor
bind
target
cell
proteas
activ
protein
cleav
expos
enzym
target
site
leav
subunit
free
mediat
viral
fusion
entri
cov
enter
target
cell
via
two
pathway
one
endocytosi
pathway
direct
fusion
cellular
surfac
exampl
sarscov
enter
target
cell
endocytosi
pathway
protein
cleav
activ
phdepend
cystein
proteas
cathepsin
l
endosom
hand
recent
studi
consist
report
sarscov
protein
also
cleav
activ
transmembran
proteas
serin
human
airway
trypsinlik
proteas
locat
cell
surfac
thu
activ
allow
protein
mediat
sarscov
infect
plasma
membran
accord
find
matsuyama
et
al
report
peptid
effici
inhibit
sarscov
entri
cell
lysosometrop
reagent
fail
inhibit
similarli
also
capac
promot
entri
merscov
bypass
endocytosi
pathway
directli
activ
protein
cellular
surfac
recent
sever
studi
report
highli
express
human
respiratori
epitheli
cell
surfac
even
associ
sever
cov
receptor
henc
plasma
membran
fusion
pathway
seem
prefer
choic
hcov
infect
human
respiratori
tract
consist
previou
studi
found
fusion
inhibitor
effect
inhibit
merscov
infect
vivo
intranas
administr
studi
also
report
current
clinic
isol
sensit
cell
surfac
endosom
cathepsin
overal
current
circul
hcov
emerg
hcov
cell
surfac
fusion
pathway
human
respiratori
tract
would
appear
import
therefor
peptid
fusion
inhibitor
strategi
intranas
administr
excel
choic
prevent
hcov
infect
via
airway
key
site
hcov
rapidli
establish
infect
wide
spread
organ
current
circul
hcov
pose
potenti
threat
human
moreov
almost
certain
zoonot
cov
transmit
human
futur
avail
hcovspecif
drug
broadspectrum
inhibitori
activ
therefor
import
prevent
control
futur
hcov
epidem
fusion
inhibitor
peptid
target
conserv
site
spike
hypervari
rbd
region
potent
broad
inhibitori
activ
multipl
hcov
infect
nasal
administr
exhibit
effect
broadli
antihcov
activ
satisfactori
safeti
profil
vivo
henc
promis
candid
develop
antivir
agent
infect
multipl
hcov
especi
use
infant
elderli
well
immunocompromis
patient
would
vulner
hcov
infect
meanwhil
studi
provid
clue
method
develop
peptid
fusion
inhibitor
potenc
breadth
inhibit
infect
highli
pathogen
envelop
virus
class
membran
fusion
protein
ebola
marburg
virus
hendra
nipah
virus
influenza
virus
cell
line
vero
obtain
american
type
cultur
collect
atcc
manassa
va
usa
cell
line
cultur
dulbecco
modifi
eagl
medium
dmem
fetal
bovin
serum
fb
strain
obtain
atcc
origin
provid
h
feldmann
nation
institut
health
nation
institut
allergi
infecti
diseas
rocki
mountain
laboratori
hamilton
mt
r
fouchier
erasmu
medic
center
rotterdam
netherland
paaviresegfp
plasmid
strain
amsterdam
preserv
laboratori
dna
sequenc
protein
delet
amino
acid
c
terminu
synthes
dna
encod
contain
ctermin
acid
delet
provid
f
li
peptid
synthes
karebay
biochem
puriti
test
highperform
liquid
chromatographi
sequenc
lkvllyeefklleslimeileyqkdsdikenaedtk
phylogenet
tree
construct
use
access
number
use
phylogenet
analysi
follow
bcov
pedv
mhv
ibv
merscov
sarscov
pdcov
code
sequenc
peptid
individu
fuse
end
domain
sarscov
merscov
residu
respect
acid
linker
sggrgg
result
sequenc
encod
differ
fusion
protein
subclon
modifi
vector
contain
tag
upstream
multipl
clone
site
result
construct
express
escherichia
coli
overnight
lb
medium
initi
purifi
fusion
protein
use
histalon
resin
clontech
elut
fraction
histalon
column
mix
enzym
ww
dialyz
buffer
mm
trishcl
ph
mm
nacl
mm
dithiothreitol
overnight
sumo
tag
cleavag
sampl
reload
onto
histalon
column
flowthrough
fraction
contain
untag
pool
concentr
gelfilt
buffer
b
mm
tri
ph
mm
nacl
hiload
superdex
ge
healthcar
column
peak
fraction
contain
trimer
pool
concentr
mgml
centrifug
emd
millipor
initi
crystal
condit
screen
use
sittingdrop
vapor
diffus
method
mosquito
crystal
robot
ttp
labtech
diffractionqu
crystal
sar
fusion
protein
obtain
use
hangingdrop
vapor
diffus
method
mix
equal
volum
protein
solut
mgml
reservoir
solut
bistri
ph
diffractionqu
crystal
mer
fusion
protein
obtain
similar
method
kscn
ph
hepe
ph
respect
diffract
data
collect
beamlin
shanghai
synchrotron
radiat
facil
ssrf
china
process
program
summari
data
collect
statist
provid
tabl
structur
sar
solv
molecular
replac
implement
phaser
program
phenix
program
use
sarscov
fusion
core
structur
protein
data
bank
pdb
search
model
structur
determin
mer
merscov
fusion
core
pdb
sarscov
fusion
core
pdb
use
search
model
structur
model
improv
cycl
manual
build
refin
use
coot
phenix
program
qualiti
model
analyz
molprob
summari
structur
refin
statist
also
given
tabl
figur
prepar
use
pymol
program
pymol
molecular
graphic
system
version
llc
electrostat
calcul
perform
model
deriv
homolog
model
use
swiss
model
websit
templat
obtain
crystal
structur
sar
mer
templat
protein
obtain
crystal
structur
relax
stabil
interact
correspond
initi
model
optim
perform
energi
minim
follow
molecular
dynam
simul
use
suit
wwwschrodingercom
simul
system
solvat
fullatom
water
contain
na
ion
concentr
mimic
physiolog
ionic
strength
simul
temperatur
pressur
p
kept
constant
k
atm
respect
circular
dichroism
spectra
nm
collect
spectropolarimet
jasco
inc
japan
evalu
secondari
structur
peptid
complex
individu
peptid
complex
dissolv
pb
final
concentr
thermal
denatur
peptid
complex
monitor
nm
thermal
gradient
midpoint
tm
valu
acquir
jasco
softwar
util
pseudoviru
bear
cov
protein
vsvg
protein
defect
genom
express
luciferas
report
produc
cell
previous
describ
titer
quantit
use
elisa
pseudoviru
use
infect
target
cell
cell
pseudotyp
sarscov
per
well
plate
presenc
absenc
test
peptid
indic
concentr
twelv
hour
infect
cultur
medium
refresh
incub
addit
hour
follow
wash
cell
pb
lyse
cell
lysi
reagent
promega
transfer
cell
lysat
costar
flatbottom
luminomet
plate
corn
costar
detect
rel
light
unit
use
firefli
luciferas
assay
kit
promega
ultra
luminomet
tecan
previous
describ
effector
cell
transfect
plasmid
paaviresegfp
encod
egfp
tegfp
cell
plasmid
paaviressegfp
encod
correspond
hcov
protein
thcov
sgfp
cell
effector
cell
cell
express
variou
hcov
receptor
membran
surfac
use
target
cell
describ
merscov
smediat
cellcel
fusion
effector
cell
tmerscovgfp
target
cell
cell
cocultur
dmem
contain
fb
hour
smediat
cellcel
fusion
effector
cell
target
cell
cell
cocultur
dmem
contain
fb
hour
sarscov
slcov
smediat
cellcel
fusion
effector
cell
tsarscovgfp
tslcovgfp
target
cell
cell
cocultur
presenc
trypsin
ngml
dmem
without
fb
hour
smediat
cellcel
fusion
effector
cell
target
cell
cell
cocultur
presenc
trypsin
ngml
dmem
without
fb
hour
five
field
well
randomli
select
count
fuse
unfus
cell
fuse
cell
least
twice
larg
unfus
cell
fluoresc
intens
fuse
cell
becam
weak
result
diffus
enhanc
green
fluoresc
protein
egfp
one
effector
cell
target
cell
see
fig
percentag
cellcel
fusion
number
fuse
cellsnumb
fuse
unfus
cell
calcul
inhibitori
activ
test
peptid
hcov
smediat
cellcel
fusion
determin
previous
describ
briefli
effector
cell
tsgfp
target
cell
cell
cocultur
presenc
absenc
test
peptid
indic
concentr
fusion
count
fuse
unfus
cell
percentag
cellcel
fusion
calcul
describ
percent
inhibit
cellcel
fusion
calcul
use
follow
formula
describ
elsewher
e
n
p
n
e
repres
percentag
cellcel
fusion
experiment
group
p
repres
percentag
cellcel
fusion
posit
control
group
thcov
segfp
cell
use
effector
cell
pb
ad
n
percentag
cellcel
fusion
neg
control
group
tegfp
cell
use
effector
cell
calcul
use
calcusyn
softwar
provid
c
chou
sampl
test
triplic
experi
repeat
twice
hcov
fusion
assay
perform
describ
elsewher
briefli
cell
cell
use
target
cell
entri
merscov
blamvpr
virion
sarscov
blamvpr
virion
respect
target
cell
cultur
hour
sixwel
plate
virion
contain
blamvpr
equival
ng
per
well
presenc
absenc
indic
concentr
cell
wash
pb
resuspend
dmem
incub
substrat
room
temperatur
hour
describ
manufactur
invitrogen
germani
last
cell
monitor
via
flow
cytometri
virion
fusion
target
cell
emiss
nm
substrat
could
cleav
blamvpr
emiss
nm
flow
cytometr
data
collect
bd
facsdiva
analyz
flowjo
inhibitori
activ
peptid
replic
cell
assess
describ
elsewher
briefli
mix
test
peptid
grade
concentr
incub
min
mixtur
appli
triplic
onto
monolay
cell
grown
microtit
plate
day
infect
viral
titer
cultur
medium
test
calcul
basi
cytopath
effect
cpe
inhibitori
activ
test
peptid
replic
cell
replic
cell
evalu
similar
way
describ
inhibitori
activ
peptid
merscov
replic
test
cell
use
modifi
standard
microneutr
assay
previous
describ
briefli
serial
twofold
dilut
peptid
incub
merscov
mem
medium
supplement
fb
medium
duplic
well
plate
min
room
temperatur
one
hundr
microlit
peptidemerscov
mixtur
transfer
confluent
cell
grown
plate
well
cell
cultur
medium
without
viru
includ
assay
posit
neg
control
respect
advanc
cpe
cell
could
develop
within
hour
respons
merscov
infect
higher
multipl
infect
moi
observ
promin
format
cpe
hour
infect
estim
moi
henc
accur
measur
efficaci
peptid
inhibitor
merscov
infect
harvest
supernat
hour
quantifi
infecti
viru
titer
standard
vero
infect
assay
express
titer
pregnant
balbc
mice
day
purchas
depart
laboratori
anim
scienc
fudan
univers
separ
four
group
deliveri
offspr
eleven
newborn
mice
chosen
group
mice
prevent
treatment
group
intranas
administ
peptid
mgkg
pb
min
intranas
challeng
viral
dose
dmem
mice
viral
control
group
normal
control
group
intranas
administ
pb
min
viral
challeng
without
viral
challeng
mous
surviv
rate
bodi
weight
variat
record
week
infect
day
infect
five
mice
group
randomli
select
euthanasia
collect
assess
viral
titer
mous
brain
briefli
mice
express
human
randomli
separ
three
group
n
viral
control
prophylact
group
therapeut
group
viral
control
therapeut
group
mous
challeng
intranas
ie
median
lethal
dose
merscov
volum
min
viral
challeng
treat
via
intranas
rout
pb
pb
respect
prophylact
group
mice
pretreat
via
intranas
rout
per
mous
min
viral
challeng
challeng
mice
monitor
daili
weight
loss
mortal
interim
two
mice
randomli
euthan
two
six
group
day
challeng
determin
lung
viru
titer
cpe
vero
express
six
balbc
femal
mice
week
old
randomli
assign
two
group
nasal
administ
pb
n
pb
without
peptid
n
control
background
fluoresc
measur
one
hour
later
mice
imag
distribut
ivi
lumina
k
seri
iii
vivo
imag
system
perkinelm
waltham
usa
mice
euthan
intraperiton
inject
sodium
pentobarbit
obtain
lung
liver
kidney
spleen
heart
imag
measur
fluoresc
valu
relev
radiant
effici
p
calcul
live
imag
softwar
cytotox
peptid
cell
cell
test
use
cell
count
dojindo
kumamoto
japan
briefli
cell
type
seed
well
microtit
plate
per
well
incub
hour
replac
medium
dmed
contain
grade
concentr
incub
day
solut
per
well
ad
follow
addit
incub
hour
absorb
measur
nm
previous
describ
femal
balbc
mice
week
old
assign
randomli
three
group
n
continu
administ
pb
lowdos
mgkg
highdos
mgkg
intranas
rout
everi
day
week
bodi
weight
chang
monitor
follow
week
alt
creatinin
sera
group
mice
measur
use
alt
creatinin
assay
kit
njjcbio
nanj
china
first
treatment
day
final
treatment
titer
immunoglobulin
g
sera
group
mice
evalu
elisa
week
final
treatment
four
week
administr
mice
group
mice
euthan
harvest
lung
liver
kidney
spleen
hematoxylin
eosin
stain
anim
studi
approv
institut
laboratori
anim
care
use
committe
fudan
univers
analys
independ
data
perform
student
unpair
twotail
test
statist
analys
carri
use
graphpad
prism
p
valu
less
consid
signific
p
p
p
p
calcul
use
calcusyn
softwar
